Implementation of the medicare part D prescription drug benefit is associated with antiretroviral therapy interruptions

Moupali Das-Douglas, Elise D. Riley, Kathleen Ragland, David Guzman, Richard Clark, Margot B. Kushel, David Bangsberg

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Antiretroviral (ARV) treatment interruptions are associated with virologic rebound, drug resistance, and increased morbidity and mortality. The Medicare Part D prescription drug benefit, implemented on January 1st, 2006, increased consumer cost-sharing. Consumer cost-sharing is associated with decreased access to medications and adverse clinical outcomes. We assessed the association of Part D implementation with treatment interruptions by studying 125 HIV-infected homeless and marginally housed individuals with drug coverage receiving ARV therapy. Thirty-five percent of respondents reported Medicare coverage and 11% reported ARV interruptions. The odds of ARV interruptions were six times higher among those with Part D coverage and remained significant after adjustment. The majority of Part D-covered respondents reporting ARV interruptions cited increased cost as their primary barrier. Directed interventions to monitor the long-term effects of increased cost burden on interruptions and clinical outcomes and to reduce cost burden are necessary to avoid preventable increases in morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalAIDS and Behavior
Volume13
Issue number1
DOIs
StatePublished - Feb 2009
Externally publishedYes

Fingerprint

Medicare Part D
Prescription Drugs
Cost Sharing
Costs and Cost Analysis
Morbidity
Mortality
Medicare
Drug Resistance
Therapeutics
HIV
Pharmaceutical Preparations
Surveys and Questionnaires

Keywords

  • Adherence
  • Cost-related medication nonadherence
  • Cost-sharing
  • HIV/AIDS
  • Medicare
  • Treatment interruption

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases
  • Social Psychology

Cite this

Implementation of the medicare part D prescription drug benefit is associated with antiretroviral therapy interruptions. / Das-Douglas, Moupali; Riley, Elise D.; Ragland, Kathleen; Guzman, David; Clark, Richard; Kushel, Margot B.; Bangsberg, David.

In: AIDS and Behavior, Vol. 13, No. 1, 02.2009, p. 1-9.

Research output: Contribution to journalArticle

Das-Douglas, Moupali ; Riley, Elise D. ; Ragland, Kathleen ; Guzman, David ; Clark, Richard ; Kushel, Margot B. ; Bangsberg, David. / Implementation of the medicare part D prescription drug benefit is associated with antiretroviral therapy interruptions. In: AIDS and Behavior. 2009 ; Vol. 13, No. 1. pp. 1-9.
@article{cfa02aa4aef74c04bb2574208e46b5ed,
title = "Implementation of the medicare part D prescription drug benefit is associated with antiretroviral therapy interruptions",
abstract = "Antiretroviral (ARV) treatment interruptions are associated with virologic rebound, drug resistance, and increased morbidity and mortality. The Medicare Part D prescription drug benefit, implemented on January 1st, 2006, increased consumer cost-sharing. Consumer cost-sharing is associated with decreased access to medications and adverse clinical outcomes. We assessed the association of Part D implementation with treatment interruptions by studying 125 HIV-infected homeless and marginally housed individuals with drug coverage receiving ARV therapy. Thirty-five percent of respondents reported Medicare coverage and 11{\%} reported ARV interruptions. The odds of ARV interruptions were six times higher among those with Part D coverage and remained significant after adjustment. The majority of Part D-covered respondents reporting ARV interruptions cited increased cost as their primary barrier. Directed interventions to monitor the long-term effects of increased cost burden on interruptions and clinical outcomes and to reduce cost burden are necessary to avoid preventable increases in morbidity and mortality.",
keywords = "Adherence, Cost-related medication nonadherence, Cost-sharing, HIV/AIDS, Medicare, Treatment interruption",
author = "Moupali Das-Douglas and Riley, {Elise D.} and Kathleen Ragland and David Guzman and Richard Clark and Kushel, {Margot B.} and David Bangsberg",
year = "2009",
month = "2",
doi = "10.1007/s10461-008-9401-5",
language = "English (US)",
volume = "13",
pages = "1--9",
journal = "AIDS and Behavior",
issn = "1090-7165",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Implementation of the medicare part D prescription drug benefit is associated with antiretroviral therapy interruptions

AU - Das-Douglas, Moupali

AU - Riley, Elise D.

AU - Ragland, Kathleen

AU - Guzman, David

AU - Clark, Richard

AU - Kushel, Margot B.

AU - Bangsberg, David

PY - 2009/2

Y1 - 2009/2

N2 - Antiretroviral (ARV) treatment interruptions are associated with virologic rebound, drug resistance, and increased morbidity and mortality. The Medicare Part D prescription drug benefit, implemented on January 1st, 2006, increased consumer cost-sharing. Consumer cost-sharing is associated with decreased access to medications and adverse clinical outcomes. We assessed the association of Part D implementation with treatment interruptions by studying 125 HIV-infected homeless and marginally housed individuals with drug coverage receiving ARV therapy. Thirty-five percent of respondents reported Medicare coverage and 11% reported ARV interruptions. The odds of ARV interruptions were six times higher among those with Part D coverage and remained significant after adjustment. The majority of Part D-covered respondents reporting ARV interruptions cited increased cost as their primary barrier. Directed interventions to monitor the long-term effects of increased cost burden on interruptions and clinical outcomes and to reduce cost burden are necessary to avoid preventable increases in morbidity and mortality.

AB - Antiretroviral (ARV) treatment interruptions are associated with virologic rebound, drug resistance, and increased morbidity and mortality. The Medicare Part D prescription drug benefit, implemented on January 1st, 2006, increased consumer cost-sharing. Consumer cost-sharing is associated with decreased access to medications and adverse clinical outcomes. We assessed the association of Part D implementation with treatment interruptions by studying 125 HIV-infected homeless and marginally housed individuals with drug coverage receiving ARV therapy. Thirty-five percent of respondents reported Medicare coverage and 11% reported ARV interruptions. The odds of ARV interruptions were six times higher among those with Part D coverage and remained significant after adjustment. The majority of Part D-covered respondents reporting ARV interruptions cited increased cost as their primary barrier. Directed interventions to monitor the long-term effects of increased cost burden on interruptions and clinical outcomes and to reduce cost burden are necessary to avoid preventable increases in morbidity and mortality.

KW - Adherence

KW - Cost-related medication nonadherence

KW - Cost-sharing

KW - HIV/AIDS

KW - Medicare

KW - Treatment interruption

UR - http://www.scopus.com/inward/record.url?scp=58149098900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149098900&partnerID=8YFLogxK

U2 - 10.1007/s10461-008-9401-5

DO - 10.1007/s10461-008-9401-5

M3 - Article

VL - 13

SP - 1

EP - 9

JO - AIDS and Behavior

JF - AIDS and Behavior

SN - 1090-7165

IS - 1

ER -